

# Curriculum vitae

---

**Name** Katrin S. Lindenberg  
**Working address:** Ulm University Hospital  
Department of Neurology  
Oberer Eselsberg 45/1  
89081 Ulm  
+49 (0)731/ 500 63103  
+49 (0)151/ 584 18278  
[katrin.lindenberg@uni-ulm.de](mailto:katrin.lindenberg@uni-ulm.de)

## Degrees

---

Board certification in Neurology	Ulm University Hospital	2017
Full medical license	Ulm University	2011
Ph.D.	Ulm University	2003
Diplom in Molecular Biology	Albert-Ludwigs University Freiburg	1998

## Employment

---

2017-present	Staff neurologist, Department of Neurology, Ulm University
2011-2017	Residency, Department of Neurology, Ulm University
2006- 2011	Senior Research Fellow, Department of Neurology, Ulm University
2004- 2006:	Research Fellow, Massachusetts General Hospital, Department of Neurology. Charlestown. Lab. head: Prof. Dr. Anne B. Young
2003-2004:	Research Fellow, Massachusetts General Hospital, Department of Neurology. Charlestown. Lab. head: Prof. Dr. Dimitri Krainc
2002-2003	Research Fellow, Department of Neurology, University of Ulm

## Education and Training

---

2007-2011	Medical School, Albert-Ludwigs-University Freiburg and Ulm University, clinical curriculum
2002	RIKEN Brain Science Institute, Laboratory for Structural Neuropathology, Wako, Japan, Supervisor: Prof. Dr. Nobuyuki Nukina.
2000-2003	Medical School, Ulm University, preclinical curriculum
2000-2002	PhD Student, Department of Neurology, University of Ulm, Germany, Supervisor: Prof. Dr. G. Bernhard Landwehrmeyer.
1998-2000	PhD Student, Department of Neurology, Albert-Ludwigs-University, Freiburg, Germany, Supervisor: Dr. G. Bernhard Landwehrmeyer.
1997-1998	Diploma thesis in Biology, Department of Human Genetics, Albert-Ludwigs-University Freiburg, Germany, Supervisor: Dr. Gerd Scherer, PhD.
1996-1998	Undergraduate training in Biology, Albert-Ludwigs-University, Freiburg, Germany
1995-1996	Undergraduate training in Biology, University of Edinburgh, UK
1991-1995	Undergraduate training in Biology, Albert-Ludwigs-University, Freiburg, Germany

---

**University level teaching**


---

Since 2015	„Practical training in Laboratory Methods“ practical course for master students in molecular medicine, Ulm University
Since 2015	Neurology II, clinical course for 4th year medical student
2011-2015	Neurology I, clinical course for 3rd year medical student
Since 2011	„Medical Neurosciences“ for master students in biology, Ulm University
2009-2013	Seminar: „amino acids“ for pre-clinical medical students, Ulm University
2008-2009	Modul I+II „Lehren und Lernen“, Hochschuldidaktikzentrum Baden-Württemberg
Since 2008	„From Basic to Clinical Neuroscience“ for master students in molecular medicine, Ulm University
2005	Tutor at Harvard Medical School for the course “Human Nervous System and Behaviour”. Course Director: Prof. Dr. David L. Cardoso

---

**Grants**


---

2014	EHDN-Seedfund (Exercise for NeuroSkeletal Enhancement In Neurological diseases (EINSTEIN study) (Co-Investigator)
2013	EHDN-Seedfund (Development of MRI based fat imaging strategies for Huntington’s Disease) (Project leader)
2012	Virtual Helmholtz-Institute „RNA dysmetabolism in neurodegeneration“, Co-Investigator WP2
2008	Baustein-Förderung Ulm University (Proteom-Analyse mitochondrialer Proteine beim Morbus Huntington) (Project leader)

---

**Awards**


---

2003	Dissertation Award, University Society, Ulm
2000-2002	DFG Fellowship as a Member of the Graduate College “Molecular and Diagnostic Concepts in Molecular Medicine”
2000	Poster Award of the German Society of Neurogenetics

---

**Additional skills**


---

2017	Course on Genetic counselling in Neurology (Qualifikation zur fachgebundenen genetischen Beratung)
2008	Co-organizer of the symposium: “The metabolic system as a therapeutic target in HD”, 05.-08.06.2008, Schloss Reisenburg .
2001-2002	Speaker of the Graduate College „Molecular and Diagnostic Concepts in Molecular Medicine“.
2001	Course in Radiation safety (Grundkurs im Strahlenschutz im nichtmedizinischen Bereich), GSF- Forschungszentrum für Umwelt und Gesundheit, Neuherberg, Germany.
2000	Course on safety in handling and experimenting with genetically modified organisms (“Sicherheit in der Gentechnik“)
2000	Basic course in laboratory animal science according to the guidelines of the Federation of European Laboratory Animal Science Association (FELASA), category c (for scientists).

---

## Professional Societies

Society for Neuroscience  
 Deutsche Gesellschaft für Neurologie (DGN)  
 European Huntingtons Disease Network (EHDN)

---

## References (peer reviewed)

1. Buck E, Bayer H, [Lindenberg KS](#), Hanselmann J, Pasquarelli N, Ludolph AC, Weydt P, Witting A: Comparison of Sirtuin 3 Levels in ALS and Huntington's Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models. *Front Mol Neurosci.* 2017; (10):156. doi: 10.3389/fnmol.2017.00156. eCollection 2017.
2. Buck E, Zügel M, Schumann U, Merz T, Gump AM, Witting A, Steinacker JM, Landwehrmeyer GB, Weydt P, Calzia E, [Lindenberg KS](#): High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function. *PLoS One.* 2017 Apr 13;12(4):e0175248. doi: 10.1371/journal.pone.0175248. eCollection 2017.
3. Hering T, Braubach P, Landwehrmeyer GB, [Lindenberg KS](#), Melzer W.: Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington's Disease. *PLoS One.* 2016 Nov 7;11(11):e0166106. doi: 10.1371/journal.pone.0166106. eCollection 2016.
4. Bayer H, Lang K, Buck E, Higelin J, Barteczko L, Pasquarelli N, Sprissler J, Lucas T, Holzmann K, Demestre M, [Lindenberg KS](#), Danzer KM, Boeckers T, Ludolph AC, Dupuis L, Weydt P, Witting A: ALS-causing mutations differentially affect PGC-1 $\alpha$  expression and function in the brain vs. peripheral tissues. *Neurobiol Dis.* 2017 Jan;97(Pt A):36-45. doi: 10.1016/j.nbd.2016.11.001. Epub 2016 Nov 3.
5. Braubach P, Orynbayev M, Andronache Z, Hering T, Landwehrmeyer GB, [Lindenberg KS](#), Melzer W: Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease. *Journal of General Physiology* 2014 Nov;144(5):393-413. doi: 10.1085/jgp.201411255.
6. [Lindenberg KS](#), Weydt P, Müller HP, Bornstedt A, Ludolph AC Landwehrmeyer GB, Rottbauer W, Kassubek J, Rasche V: Two-point magnitude MRI for rapid mapping of brown adipose tissue and its application to the R6/2 mouse model of Huntington disease. *PLoS One.* 2014;9(8):e105556. doi: 10.1371/journal.pone.0105556. eCollection 2014.
7. Beck H, Flynn K, [Lindenberg KS](#), Schwarz H, Bradke F, Di Giovanni S, Knöll B.: Serum Response Factor (SRF)-cofilin-actin signaling axis modulates mitochondrial dynamics. *PNAS:* 109 (38): E2523-32. Epub 2012 Aug 27.
8. Euler P, Friedrich B, Ziegler R, Kuhn A, [Lindenberg KS](#), Weiller C, Zucker B.: Gene expression analysis on a single cell level in Purkinje cells of Huntington's disease transgenic mice. *Neurosci Lett.* 2012 May 23; 517(1):7-12.
9. Dong X, Zong S, Witting A, [Lindenberg KS](#), Kochanek S, Huang B.: Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration. *J Gene Med.* 2012 Jul;14(7):468-81.
10. Zucker B, Kama JA, Kuhn A, Thu D, Orlando LR, Dunah AW, Gokce O, Taylor DM, Lambeck J, Friedrich B, [Lindenberg KS](#), Faull RLM, Weiller C, Young AB, Luthi-Carter R: Decreased Lin7b Expression in Layer 5 Pyramidal Neurons May Contribute to Impaired Corticostriatal Connectivity in Huntington Disease. *Journal of Neuropathology and Experimental Neurology* (2010) **69**: 880-95.
11. Kosinski CM, Schlangen C, Gellerich FN, Gizatullina Z, Deschauer M, Schiefer J, Young AB, Landwehrmeyer GB, Toyka KV, Sellhaus B, [Lindenberg KS](#).: Myopathy as a first symptom of Huntington's disease in a Marathon runner. *Movement Disorder* (2007): **22**:1637-40.

12. Khan LA, Bauer PO, Miyazaki H, Lindenberg KS, Landwehrmeyer BG, Nukina N: Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in *Caenorhabditis elegans*. *Journal of Neurochemistry* (2006): **98**: 576-87.
13. Gizatullina ZZ, Lindenberg KS, Harjes P, Chen Y, Kosinski CM, Landwehrmeyer GB, Ludolph AC, Striggow F, Zierz S, Gellerich FN: Low stability of Huntington muscle mitochondria against Ca<sup>2+</sup> in R6/2 mice. *Annals of Neurology* (2006). **59**: 407-11.
14. Saft C, Zange J, Andrich J, Müller K, Lindenberg K, Landwehrmeyer GB, Vorgerd M, Kraus PH, Przuntek H, Schöls L: Mitochondrial impairment in patients and asymptomatic gene carriers of Huntington's disease. *Movement disorders*. (2005) **20**: 674-9.
15. Sarikas A, Carrier L, Schenke C, Flavigny J, Lindenberg KS, Eschenhagen T, Zolk O: Impairment of the ubiquitin-proteasome system by mutant cardiac myosin binding protein C. *Cardiovascular Research* (2005) **66**: 33-44
16. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang C, Mootha VK, Jäger S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, Spiegelman BM: Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1 $\alpha$  null mice. *Cell* (2004) **119**: 121-135.
17. Goehler H, Lalowski M, Stelzl U, Waelter S, Stroedicke M, Worm U, Droege A, Lindenberg KS, Knoblich M, Haenig C, Herbst M, Suopanki J, Scherzinger E, Abraham C, Bauer B, Hasenbank R, Fritzsche A, Ludewig AH, Buessow K, Coleman SH, Gutekunst CA, Landwehrmeyer GB, Lehrach H, Wanker EE: A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. *Molecular Cell* (2004) **15**: 853-865.
18. Pop R, Conz C, Lindenberg KS, Blesson S, Schmalenberger B, Briault S, Pfeifer D, Scherer G: Screening of the 1 MB SOX9 5' control region by array CGH identifies a large deletion in a case of campomelic dysplasia with XY sex reversal. *Journal of Medical Genetics* (2004) **41**: e47.
19. von Horsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AM, Paul M, Jones L, Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O: Transgenic rat model of Huntington's Disease. *Human Molecular Genetics* (2003) **12**: 617-624.
20. Lunke A, Lindenberg KS, Ben-Haïem L, Weber C, Devys D, Landwehrmeyer GB, Mandel JL, Trottier Y: Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. *Molecular Cell* (2002) **10**:259-269.
21. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB: Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. *Brain* (2002) **125**:1908-1922.
22. Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J, Rechsteiner M, Riess O, Landwehrmeyer GB: Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. *Annals of Neurology* (2002) **51**:302-310.
23. Yvert G, Lindenberg KS, Devys D, Helmlinger D, Landwehrmeyer GB, Mandel JL: SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. *Human Molecular Genetics* (2001) **10**:1679-1692.
24. Yvert G, Lindenberg KS, Picaud S, Landwehrmeyer GB, Sahel JA, Mandel JL: Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. *Human Molecular Genetics* (2000) **9**: 2491-2506.
25. Lindenberg KS, Yvert G, Müller K, Landwehrmeyer GB: Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation. *Brain Pathology* (2000) **10**:385-394.